2021³â ´ëÇÑÁ¤½Å¾à¹°ÇÐȸ Ãß°èÇмú´ëȸ ¹× ¿¬¼ö±³À° : 2021-10-01±³À°ÀÏÀÚ : 2021-10-01
±³À°Àå¼Ò : ¼¿ï ¹é¹ü±è±¸±â³ä°ü ÄÁº¥¼ÇȦ ¹× ´ëȸÀǽÇ
±³À°ÁÖÁ¦ :
2021³â ´ëÇÑÁ¤½Å¾à¹°ÇÐȸ Ãß°èÇмú´ëȸ ¹× ¿¬¼ö±³À°ÁÖÃÖ±â°ü : ´ëÇÑÁ¤½Å¾à¹°ÇÐȸ
´ã´çÀÚ : À̼¼Àº
¿¬¶ôó : 02-784-2742
À̸ÞÀÏ :
secretariat@kcnp.or.kr ±³À°Á¾·ù : Á¤½Å°Ç°ÀÇÇаú
Âü¼®¿¹»óÀοø : 100¸í
Èñ¸ÁÆòÁ¡ : 4Á¡
Áö¿ª :
¼¿ïƯº°½Ã±³À°½Ã°£ : 7 ½Ã°£ 35ºÐ
¼¼ºÎ¼ö°·á : 40,000¿ø
ºñ°í »çÀüµî·Ïºñ Æò»ýȸ¿ø ¸éÁ¦/Á¤È¸¿ø 20,000¿ø/ºñȸ¿ø 30,000¿ø/ÁØȸ¿ø¹×±âŸ 10,000¿ø/´çÀϵî·Ïºñ Æò»ýȸ¿ø 10,000¿ø/Á¤È¸¿ø 30,000¿ø/ºñȸ¿ø 40,000¿ø/ÁØȸ¿ø ¹× ±âŸ 20,000¿ø
±¸ºÐ ¿ùÀÏ °ÀÇ½Ç ½Ã°£ ±³À°Á¦¸ñ °»ç¸í(¼Ò¼Ó) Çʼö°ú¸ñ
±³À°½Ã°£ 10-01 ÄÁº¥¼ÇȦ 13:25~13:50 Efficacy of Duloxetine on depression and pain in cancer patients Á¤Á¾Çö(°¡Å縯ÀÇ´ë)
±³À°½Ã°£ 10-01 ´ëȸÀÇ½Ç 13:00~13:50 Reliable long-term management that prevents recurrences and preserves functioning in bipolar disorder Àå½ÂÈ£(¿ø±¤ÀÇ´ë)
Åä·Ð 10-01 ÄÁº¥¼ÇȦ 13:50~14:05 Consensus of definition of TRD ¼ºÇü¸ð/Àå¼¼Çå/¹Ú¿µ¹Î/±è¿ø(¼øõÇâÀÇ´ë/ºÀ»ýº´¿ø/ÀÎÁ¦ÀÇ´ë/ÀÎÁ¦ÀÇ´ë)
Åä·Ð 10-01 ÄÁº¥¼ÇȦ 14:05~14:20 Pharmacological management for TRD ¼ºÇü¸ð/Àå¼¼Çå/¹Ú¿µ¹Î/±è¿ø(¼øõÇâÀÇ´ë/ºÀ»ýº´¿ø/ÀÎÁ¦ÀÇ´ë/ÀÎÁ¦ÀÇ´ë)
Åä·Ð 10-01 ÄÁº¥¼ÇȦ 14:20~14:40 Non-pharmacological management for TRD ¼ºÇü¸ð/Àå¼¼Çå/¹Ú¿µ¹Î/±è¿ø(¼øõÇâÀÇ´ë/ºÀ»ýº´¿ø/ÀÎÁ¦ÀÇ´ë/ÀÎÁ¦ÀÇ´ë)
±³À°½Ã°£ 10-01 ´ëȸÀÇ½Ç 13:50~14:15 When could Vortioxetine be a relevant treatment option for patients with MDD living through the pandemic? ÀÌ°¼ö(Â÷ÀÇ°úÇдë)
±³À°½Ã°£ 10-01 ´ëȸÀÇ½Ç 14:15~14:40 Dose-response relationship among antidepressant treatment option and for Vortioxetine ¿Õ¼º¹Î(°¡Å縯ÀÇ´ë)
ÈÞ½Ä 10-01 14:40~14:55 ()
±³À°½Ã°£ 10-01 ÄÁº¥¼ÇȦ 14:55~15:20 Eye-contact game using mixed reality for the treatment of children with attention deficit hyperactivity disorder ±è±â¹ü(ÇѾç´ë ¿¡¸®Ä« ¼ÒÇÁÆ®¿þ¾î À¶ÇÕ´ëÇÐ)
±³À°½Ã°£ 10-01 ÄÁº¥¼ÇȦ 15:20~15:45 Virtual school and VR game addiction treatment program for adolescents and young adults ±èÀºÁÖ(¿¬¼¼ÀÇ´ë)
±³À°½Ã°£ 10-01 ÄÁº¥¼ÇȦ 15:45~16:05 Are digital therapeutics appropriate for individuals with ASD? À¯ÈñÁ¤(¼¿ïÀÇ´ë)
±³À°½Ã°£ 10-01 ´ëȸÀÇ½Ç 14:55~15:20 Homeostasis and allostasis ÀüÈ«ÁØ(°Ç±¹ÀÇ´ë)
±³À°½Ã°£ 10-01 ´ëȸÀÇ½Ç 15:20~15:45 Allostasis in addiction Á¤¿µÃ¶(¿¬¼¼ÀÇ´ë)
±³À°½Ã°£ 10-01 ´ëȸÀÇ½Ç 15:45~16:05 Allostasis in mood disorder ³ë´ë¿µ(ÇѸ²ÀÇ´ë)
±³À°½Ã°£ 10-01 ÄÁº¥¼ÇȦ 16:05~16:30 Classic pharmacotherapy for AD and its limitations ÀÓÇö±¹(°¡Å縯ÀÇ´ë)
±³À°½Ã°£ 10-01 ÄÁº¥¼ÇȦ 16:30~16:55 Amyloid-¥â/tau-targeting immunotherapy and its limitations ¼½Â¿Ï(ÇѸ²ÀÇ´ë)
±³À°½Ã°£ 10-01 ÄÁº¥¼ÇȦ 16:55~17:15 Newly approved drug: Aducanumab ¾öÀ¯Çö(°¡Å縯ÀÇ´ë)
±³À°½Ã°£ 10-01 ´ëȸÀÇ½Ç 16:05~16:30 Pathophysiology in postpartum depression ÀÓÀº¼º(½Å¼¼°èÈ¿º´¿ø)
±³À°½Ã°£ 10-01 ´ëȸÀÇ½Ç 16:30~16:55 Prevention and risk factor control for PPD °ÇÑ°íÀººñ(±¹¸³³ªÁÖº´¿ø)
±³À°½Ã°£ 10-01 ´ëȸÀÇ½Ç 16:55~17:15 Allopregnanolone in PPD: Brexanolone È«Á¤¿Ï(Àͻ꺴¿ø)